Blair William & Co. IL Reduces Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Blair William & Co. IL lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 14.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 257,069 shares of the medical equipment provider’s stock after selling 43,740 shares during the quarter. Blair William & Co. IL owned 0.11% of Hologic worth $19,087,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Innealta Capital LLC purchased a new stake in shares of Hologic in the second quarter worth about $25,000. iA Global Asset Management Inc. purchased a new stake in shares of Hologic in the first quarter worth about $37,000. Cranbrook Wealth Management LLC purchased a new stake in shares of Hologic in the second quarter worth about $47,000. Mather Group LLC. purchased a new stake in shares of Hologic in the first quarter worth about $48,000. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on HOLX. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Evercore ISI upped their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their price target on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares of the company’s stock, valued at $3,615,024. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is currently owned by insiders.

Hologic Price Performance

Shares of Hologic stock opened at $82.40 on Friday. The business has a 50 day simple moving average of $80.63 and a two-hundred day simple moving average of $77.01. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The stock has a market capitalization of $19.23 billion, a P/E ratio of 42.04, a PEG ratio of 2.53 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the firm earned $0.93 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.